CompletedPHASE1, PHASE2NCT02327078
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Studying Malignant germ cell tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Lance Leopold, MDIncyte Corporation
- Intervention
- Nivolumab(drug)
- Enrollment
- 307 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2020
Study locations (24)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- The Angeles Clinic and Research Institute, Los Angeles, California, United States
- USC Norris Cancer Center, Los Angeles, California, United States
- UCSF - University of California San Francisco, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- The University of Kansas Clinical Research Center, Fairway, Kansas, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
- NYU Cancer Center, New York, New York, United States
- Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Wake Forest Medical Center Boulevard, Winston-Salem, North Carolina, United States
- Sanford Research, Fargo, North Dakota, United States
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
- +9 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02327078 on ClinicalTrials.govOther trials for Malignant germ cell tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04804007Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCTNabil Adra
- RECRUITINGPHASE1NCT04038619Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI)